New hope for rare blood disorder: daratumumab studied in iTTP patients
NCT ID NCT07513948
First seen Apr 14, 2026 · Last updated May 16, 2026 · Updated 3 times
Summary
This study looks at how well the drug daratumumab works and how safe it is for people with a rare blood clotting disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP). It includes 40 adults whose disease did not get better with standard treatments or who could not tolerate them. Researchers will track how many patients respond to daratumumab and monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
RECRUITINGMilan, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.